Guo, Q., Zhao, P., Zhang, Z., Zhang, J., Zhang, Z., Hua, Y., Han, B., Li, N., Zhao, X. and Hou, L. (2020) TIM-3 Blockade Combined with Bispecific Antibody MT110 Enhances the Anti-Tumor Effect of γδ T cells. Cancer Immunology, Immunotherapy, 69, 2571-2587.
https://doi.org/10.1007/s00262-020-02638-0

has been cited by the following article:

• TITLE: Construction of Multi-Specific Antibody by Genetic Engineering and Its Progress in Tumor Therapy

  AUTHORS: Zhenqi Xu, Can Gao, Mengru Jian, Wei Du

  KEYWORDS: Genetically Engineered, Multi-Specific Antibody, Tumor Therapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 24, 2023

  ABSTRACT: Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.